Summary
Australia Nucleic Acid Testing (NAT) Market, 2019-2023: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing
This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years.
Highlights
- Five-year test volume and sales forecasts
- Feature comparison of major analyzers
- Profiles of market players and start-up firms developing innovative technologies
and products
- Specific product and business opportunities for instrument and consumable suppliers.
Rationale
The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.
In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.
Market Segmentation Analysis
- Five-year test volume and sales forecasts for major applications, including:
- Infectious Diseases - Forensic Testing
- Cancer - Paternity Testing/HLA Typing
- Genetic Diseases - Others
- Five-year test volume and sales projections for over 30 NAT assays.
Product/Technology Review
- Comparison of leading molecular diagnostic analyzers.
- Review of molecular diagnostic technologies, test formats, detection methodologies,
trends in testing automation and over 30 target/signal amplification methods, including:
- PCR - bDNA
- SDA - NASBA
- TMA - SSSR, and others
- LCR
- Companies, universities and research centers developing new molecular-
diagnostic technologies and products.
Competitive Assessments
- Strategic profiles of major suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, collaborative arrangements and
new technologies/products in RandD.
Opportunities and Strategic Recommendations
- New product development opportunities with potentially significant market appeal
during the next five years.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Business planning issues and concerns.
Contains 1,120 pages and 48 tables
Companies Profiled
Competitive Assessments
- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Biotest
- Cepheid
- Decode Genetics
- Diadexus
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Grifols
- Hologic
- Illumina
- LabCorp
- Leica Biosystems
- Li-Cor Biosciences
- Myriad Genetics
- Ortho-Clinical Diagnostics
- PerkinElmer
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens Healthineers
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher
